JPRN-UMIN000002266已完成2 期
Prospective study of NEOadjuvant Anastrozole and RadioTherapy for hormone-responsive postmenopausal breast cancer (NEO-A-RT) - Prospective study of NEOadjuvant Anastrozole and RadioTherapy for hormone-responsive postmenopausal breast cancer (NEO-A-RT)
Osaka Medical Center for Cancer and Cardiovascular Diseases0 个研究点目标入组 35 人开始时间: 2009年7月29日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)past history of any invasive malignancy within the previous 5 years 2)past history of breast cancer or synchronous bilateral breast cancer 3)past history of radiotherapy for ipsilateral breast 4)Suspicious of allergy for radiotherapy 5)Past use of aromatase inhibitors 6)Suspicious of allergy for aromatase inhibitors 7)Patients who had received or are receiving any steroids, estrogens or selective estrogen receptor modulators 8)Any reason the physician believes that the patient is not appropriate to participate in the study
研究者
相似试验
进行中（未招募）
不适用
A randomised Phase II Study comparing anastrozole and fulvestrant to an-astrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone marrow - ABCSG 21postmenopausal women with hormone receptor positive early breast cancerEUCTR2005-005715-22-ATAstraZeneca AB176
进行中（未招募）
1 期
A randomised Phase II Study comparing anastrozole and fulvestrant to an-astrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone marrow - ABCSG 21EUCTR2005-005715-22-NOAstraZeneca AB176
进行中（未招募）
不适用
A randomised Phase II Study comparing anastrozole and fulvestrant to anastrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone marrow - ABCSG 21EUCTR2005-005715-22-DEAstraZeneca AB176
暂停
2 期
Study of neoadjuvant Letrozole combined with standerd chemotherapy for postmenopausal women with Endocrine-responsive Breast Cancer(subject of stage2,3A)Postmenopausal, hormone-receptor positive and resectable primary breast cancerJPRN-UMIN000002447iigata Cancer Center Hospital80
进行中（未招募）
不适用
A phase III study comparing anastrozole, letrozole and exemestane, upfront (for 5 years) or sequentially (for 3 years after 2 years of tamoxifen), as adjuvant treatment of postmenopausal patients with endocrine-responsive breast cancer - GIM3- FATAadjuvant hormono-therapy in breast cancer patientsMedDRA version: 6.1Level: PTClassification code 10006279EUCTR2006-004018-42-ITIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II